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Abstract 
The purpose of this review is to report and summarize previously reported studies and assess many of the individual 
steps of the intravitreal injection procedure’s possible effect on the prevention of endophthalmitis. The pooled 
endophthalmitis rate from 20 large retrospective case series of anti-VEGF injections was 144/510,396 (0.028%; 
1/3,544). Injections may be performed in an office-based location or in an operating room (OR) and low rates of 
endophthalmitis can be achieved in either location with careful attention to asepsis. Pre- or post-injection topical 
antibiotics have not been shown to be effective, and could select for more virulent microorganisms. Povidone-iodine 
prior to injection is accepted as the gold-standard antiseptic agent, but aqueous chlorhexidine may be an alterna-
tive. Antisepsis before and after gel or subconjunctival anesthetic is suggested. The preponderance of Streptococcal 
infections after intravitreal injection is discussed, including the possible role of aerosolization, which can be minimized 
by using face masks or maintaining silence. As with other invasive procedures in medicine, the use of sterile gloves, 
following adequate hand antisepsis, may be considered. Control of the eyelashes and lid margin is required to avoid 
contamination of the needle, but this can be achieved with or without a speculum. Techniques to minimize vitreous 
reflux have not been shown to reduce the risk of endophthalmitis. Same day bilateral injections should be performed 
as two separate procedures, preferably using drug from different lots, especially when using compounded drugs.
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Introduction
Intravitreal injection (IVI) is the most commonly per-
formed ophthalmic procedure. In the USA, the number 
of injections performed has increased exponentially, from 
4,215 injections in 2001 to 82,994 in 2004, to 812,413 in 
2007, to 1.27 million in 2009 and to 2.5 million injections 
in 2011 [1, 2]. Similar increases have been observed in 
Canada and the United Kingdom [3, 4].
Infectious endophthalmitis (IE) secondary to IVI is a 
potentially devastating complication. It can be difficult 
to distinguish infectious endophthalmitis from “sterile” 
or non-infectious endophthalmitis. For the purpose of 
this review, IE refers to endophthalmitis that is clinically 
suspected to be infectious, and treated as such with a vit-
reous tap and injection of antibiotics and/or vitrectomy 
surgery.
Bacteria are most likely inoculated into the vitreous 
cavity at the time of injection, or much less likely gain 
access later through the needle tract [5, 6]. The potential 
sources of bacteria include the patient’s ocular or perio-
cular surfaces, aerosolized bacteria, or contamination of 
the needle, instruments, drug or drug vial [7].
Two meta-analyses including both retrospective series 
and clinical trials have calculated the pooled rate of 
endophthalmitis after anti-VEGF injections. McCannel 
found a rate of 52/105,536 injections (0.049%; 1 in 2030) 
[8] and more recently, Fileta et al. [9] calculated a rate of 
197/350,535 (0.056%; 1 in 1,779). As patients typically 
receive ongoing intravitreal therapy, the per-patient risk 
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of endophthalmitis is significantly higher than the per-
injection risk.
The rate of needle contamination after IVI has been 
reported as between 0.36 and 18%, which is significantly 
higher than the incidence of endophthalmitis after 
IVI [5, 7, 10]. The threshold inoculum size required to 
develop endophthalmitis is related to the type of bac-
teria and their virulence, intraocular immune mecha-
nisms and anatomical characteristics of the vitreous 
[11, 12]. Animal studies have shown that a smaller num-
ber of bacterial colony-forming units are required to 
induce endophthalmitis when injected into the vitreous 
compared to when they are injected into the anterior 
chamber [13]. Endophthalmitis following intravitreal 
injection often presents earlier than after cataract sur-
gery [14, 15].
The purpose of this review is to estimate the rate of 
endophthalmitis after intravitreal injection and to exam-
ine each step of the injection procedure that may influ-
ence the risk of endophthalmitis. To be able to prove that 
a particular measure reduces the risk of endophthalmitis 
would need huge numbers of patients in a randomized 
controlled trial, given that endophthalmitis is a relatively 
rare outcome. There is thus no Level 1 evidence for any 
preventative measure to reduce the incidence of endoph-
thalmitis after intravitreal injection. As a result, this 
review largely summarizes retrospective papers, with 
their inherent biases.
Methods
A systematic literature search of the Medline database 
from 1996 to December 2014 was performed through 
Ovid, using search terms relevant to each section. Fur-
ther literature was sourced from the reference lists of 
retrieved publications.
To estimate the per-injection rate of endophthalmitis 
after anti-VEGF injection, retrospective case series with 
at least 10,000 such injections were included. Studies 
that did not report a breakdown of the drugs used were 
excluded to avoid including triamcinolone and other 
injections in this calculation. Questionnaire-based and 
population-based studies were excluded given the incom-
plete data. Clinical trials were excluded as they may not 
reflect real-world practice, with more stringent require-
ments regarding injection technique often included in 
the protocols.
Results
Twenty retrospective case series meeting the inclusion 
criteria were identified. Details of the injection procedure 
and associated aseptic measures used in each series are 
summarized in the Table 1. Where data were missing, the 
corresponding author for each study was contacted by 
email. Only two authors were not contactable.
We identified 144 cases of endophthalmitis from 
510,396 anti-VEGF injections which equates to a pooled 
endophthalmitis rate of 0.028% or 1 in 3,544 injections 
[16–33].
Review
Location—office vs operating room (OR)
In the 2013 American Society of Retinal Specialists 
(ASRS) Preferences and Trends (PAT) Survey, over 98% 
of USA-based specialists reported performing injections 
in an office setting, compared with only 47% of inter-
national specialists [34]. In Germany and other parts of 
Europe, more injections are performed in the operating 
room (OR) [35, 36].
It has been [29] suggested that an advantage of the OR 
location is the superior air circulation systems. However, 
the ESCRS endophthalmitis study group was not able to 
find a relationship between the number of air changes per 
hour and the incidence of endophthalmitis after cataract 
surgery when they compared locations with minimal air-
flow, 20 air changes per hour and ultraclean air systems 
using laminar flow principles [37, 38].
Pooling the results of three OR-based injection series, 
the endophthalmitis rate was just 6/78,506 (0.0076% or 1 
in 13,084) [19, 23, 25]. Common to these studies was the 
careful attention to asepsis with the use of sterile gloves, 
face masks, and drapes which were not used in most 
other office-based series (see Table 1). A notable excep-
tion is Shimada et al’s series with no cases of endophthal-
mitis out of 15,144 injections where similar strict aseptic 
measures were followed in an office setting [27].
Abell et  al. [29] reported an endophthalmitis rate of 
4/3,376 (0.12%) for office-based injections compared 
with 0/8,873 (0%) for OR-based injections. In this non-
randomized series, patients with private health insurance 
were treated in the OR while those without insurance 
were treated in the office. The difference in endophthal-
mitis rates may be a reflection of socioeconomic or other 
factors [39]. Tabendeh et al. [30] reported an endophthal-
mitis rate of 3/8,210 (0.037%) anti-VEGF injections in 
the office compared with 2/3,047 in the operating room 
(0.066%), in another non-randomised study that was not 
powered to be able to detect a difference. Compared with 
office-based injections, there was no apparent benefit to 
an OR environment in this small study.
Although there is no doubt that the OR has many advan-
tages, there are logistical hurdles that make access to OR 
facilities difficult for many patients, and the OR location 
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can add substantial additional cost to patients and the 
healthcare system. It has been suggested that simply being 
in an OR may alter behavior with more careful attention to 
asepsis [23]. While three series describing OR-based injec-
tions have reported low rates of endophthalmitis, this may 
reflect publication bias. Similar low rates can be achieved 
with strict asepsis in an office setting.
Hand antisepsis
The aim of surgical hand antisepsis is to reduce the bacte-
rial load at the commencement of a procedure. Broadly 
speaking there are two main types of antisepsis solutions: 
aqueous scrubs (povidone iodine, chlorhexidine and tri-
closan) and liquid or gel alcohol rubs (with or without 
additional ingredients) [40].
Alcohol-based rubs have been found to have superior 
antimicrobial efficacy compared with aqueous scrubs [40, 
41]. The reduction in microbial counts with alcohol rubs 
is rapid, and inhibition of bacterial regrowth to baseline 
levels can take more than 6 h [42]. However, unlike chlo-
rhexidine, alcohol does not bind to the skin imparting a 
true residual effect, so chlorhexidine or other agents are 
often added to alcohol rubs [40].
While chlorhexidine induces less allergic reactions 
than povidone-iodine, skin irritation, dryness and irritant 
contact dermatitis still occurs more frequently with chlo-
rhexidine scrubbing than with alcohol-based rubs [40, 
43]. Liquid alcohol-based rubs are superior to gels both 
in terms of tolerability and efficacy [44].
Alcohol-based rubs are not without limitations. They do 
not remove surface dirt because they do not contain sur-
factants or have a foaming action, and may have limited 
effectiveness if the hands are heavily contaminated [40, 
45]. Rubs may also leave a residue on the hands after use.
There is no specific evidence regarding the role of hand 
antisepsis in the context of intravitreal injection and 
most of the retrospective series do not even mention if 
or how hand antisepsis was performed. If sterile gloves 
are employed, the need for hand antisepsis could be 
questioned given the low risk of glove perforation during 
procedures of very short duration. In our opinion, atten-
tion to hand antisepsis is important for all invasive pro-
cedures in medicine. The initial antisepsis at the start of 
an injecting session should ideally include hand washing 
with soap or an aqueous scrub to mechanically remove 
any surface dirt or heavy bacterial contamination, espe-
cially if gloves are not worn [40, 46]. For subsequent 
antisepsis, alcohol-based rubs are ideal given their rapid 
action and superior dermal tolerance.
Gloves
The purpose of wearing gloves during invasive proce-
dures is to protect both the patient and the surgeon [47]. 
In a survey of retinal specialists in the USA, only 254/762 
(33%) reported wearing sterile gloves for intravitreal 
injections, while 323/762 (42%) did not wear gloves at all 
[48]. In another smaller survey of 158 retinal specialists, 
46% reported that they do not wear gloves [49]. In con-
trast, 88% of 112 surveyed retinal specialists in the United 
Kingdom reported using sterile gloves [50]. If non-sterile 
gloves are used, perforations may be more common with 
vinyl compared with latex gloves [51–53]. Non-sterile 
gloves may be more prone to fungal contamination com-
pared with individually sealed sterile gloves [54].
It has been argued that sterile gloves are not required 
as long as the tip of any instrument touching the eye 
remains sterile [48, 55, 56]. By definition, this is no longer 
“aseptic technique”, a key principle of which is that any 
part of an instrument if touched directly or indirectly 
could result in infection [57]. Sterile gloves are required 
for aseptic procedures, while non-sterile gloves suffice 
for clean procedures [57]. A “no-touch” technique with-
out gloves at all was advocated for cataract surgery over 
50 years ago, but has fallen out of favor [58].
Wound infection rates have been shown to be no 
higher with the use of non-sterile compared with sterile 
gloves when suturing the skin [59, 60] However, ster-
ile gloves are recommended for the insertion of central 
venous catheters and spinal anesthesia procedures [51, 
61, 62]. Like the CSF, the vitreous is an immune-privi-
leged site and a small inoculum of low virulence bacteria 
may be sufficient to cause endophthalmitis.
There are no studies directly examining the role of ster-
ile gloves in reducing the risk of post-injection endoph-
thalmitis, and they are often used in conjunction with 
other aseptic measures such as face masks and sterile 
drapes. We believe that intravitreal injection should be 
regarded as an aseptic procedure given that it involves 
penetration into an immune-privileged, nutrient-rich 
cavity. Similar to other aseptic procedures in medicine, 
the use of sterile gloves should be considered.
Masks
The main purpose of wearing a surgical face mask is to 
reduce bacterial contamination of the surgical field from 
the surgeon’s mouth or nasopharynx [63]. In the 2013 
ASRS PAT survey, just 14% of US-based ophthalmolo-
gists reported wearing a mask and asking the patient not 
to speak [34].
In his meta-analysis of 105,536 injections, McCannel 
found that eight of the 26 culture-positive cases (31%) 
were due to Streptococcus and noted that this was 3-fold 
higher than earlier studies of endophthalmitis after cat-
aract surgery [8]. Others have found similar results and 
have highlighted the poor visual outcomes associated 
with this virulent pathogen, with an increased likelihood 
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of a final VA of counting fingers or less and an increased 
likelihood of enucleation [14, 16, 17, 21, 64].
It is thought that the preponderance of Streptococ-
cal isolates may relate to droplet dispersal of organ-
isms while performing intravitreal injections. Viridans 
group Streptococcus species are normal commensals 
of the upper respiratory tract and oral cavity [65, 66]. 
As they are uncommonly found as part of the normal 
conjunctival flora, it has been suggested that they may 
contaminate the conjunctival surface or needle via aero-
solization, leading to endophthalmitis [8, 21]. In studies 
where conjunctival cultures were taken in treatment-
naïve eyes, the most commonly cultured organisms 
were coagulase negative Staphylococci accounting for 
65–83% of isolates, while 0–7% of isolates were Strepto-
cocci [6, 67–69].
In an experimental study designed to simulate the 
conditions during intravitreal injections, Wen et al. [70] 
found that wearing a face mask or remaining silent sig-
nificantly decreased culture plate contamination com-
pared with not wearing a face mask or turning the face 
away. They also showed that a significant number of 
colonies grew when the reclined volunteer (simulating a 
patient) continued talking. While no Streptococcal spe-
cies were isolated from the groups wearing a face mask 
or remaining silent, the proportion of bacterial colonies 
represented by oral Streptococcal species ranged from 67 
to 83% in the other groups.
In a similar study, Doshi et  al. [71] also found almost 
no bacterial growth when a mask was not worn and 
silence was not maintained, if the agar plates were pre-
treated with povidone-iodine (PI). In practice however, if 
the conjunctival surface were to be contaminated imme-
diately prior to needle entry, there may not be adequate 
time for the PI to take effect.
Friedman et  al. [72] recently demonstrated no differ-
ence in the needle contamination rates when speaking 
compared with maintaining silence.
Oral commensals have been found in cases of iatro-
genic meningitis following dural puncture procedures 
and in some cases have been molecularly matched with 
strains found in the oropharynx of the proceduralist [73–
76]. Absence of a face mask has also been implicated in 
iatrogenic septic arthritis after intraarticular injections 
[77, 78]. In these cases there is a strong suggestion that 
airborne transmission of a proceduralist’s oropharyngeal 
flora onto a needle or patient’s skin is followed by inocu-
lation into a sterile compartment.
The presence of a viral upper respiratory tract infec-
tion (URTI) has been shown to markedly increase the 
airborne dispersal of methicillin-resistant Staphylococ-
cus aureus (MRSA), which can be prevented by wearing 
a mask [79].
Several studies have shown that wearing a mask does 
not lower the risk of surgical wound infection [80–82]. 
Wen et  al. argue that oral Streptococcal species are of 
relatively low virulence in the immunocompetent host, 
which is why they are infrequently found in surgical site 
infections. However the vitreous and cerebrospinal fluid 
are immune-privileged sites where these usually less vir-
ulent strains can flourish [70, 77, 83]. Dural puncture is 
a procedure similar to intravitreal injection in that both 
involve needle penetration into a nutrient-rich body cav-
ity that can serve as a culture medium [8].
Of course, there may be other explanations for the pre-
ponderance of Streptococcal infections after intravitreal 
injections. Delayed-onset bleb-related endophthalmitis 
is also associated with a disproportionately higher rate of 
Streptococcal infection. This may be the result of altera-
tions in the resident flora or structural changes in the eye 
wall, and such changes may also occur in some eyes after 
multiple intravitreal injections [30, 84–86].
While the use of face masks has not been proven to 
reduce the risk of post-injection endophthalmitis [87], 
they have been associated with a reduction in post-oper-
ative endophthalmitis [88]. Although maintaining total 
silence may be equivalent to the wearing of a mask, it is 
often important to give patients reassurance and instruc-
tions while performing the procedure [89–91]. A mask 
may also offer protection in the event of an inadvertent 
cough or sneeze. The needle should remain capped until 
immediately before the injection [21]. Patients should be 
instructed to minimize talking before or during the pro-
cedure. Assistants involved in setting up the instruments, 
drug and sterile trays should maintain silence or wear 
a face mask, and keep the trays covered until the com-
mencement of the procedure. Patients’ relatives should 
be encouraged to wait outside the procedure room.
Antisepsis
The aim of antisepsis is to reduce the bacterial load on 
the ocular surface and the periocular structures including 
the eyelids and eyelashes, without inducing antimicro-
bial resistance or selecting for more virulent organisms 
[92]. No study to date has found a correlation between 
the number of bacteria on the ocular surface and the risk 
of developing endophthalmitis [93]. Antibiotic resistance 
does not appear to impair the utility of PI and chlorhex-
idine, the two most commonly used antiseptics [94].
Povidone‑iodine (PI)
PI is a complex of iodide and a solubilizing carrier, pol-
yvinylpyrrolidone, which acts as a reservoir of “free” 
iodine, which is the active component [95]. The iodine 
penetrates bacterial cell membranes and inactivates key 
cytosolic proteins, fatty acids and nucleotides. PI does 
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not have to be allowed to dry or evaporate to have a bac-
tericidal effect [96]. It has a broad spectrum of antimi-
crobial activity with negligible bacterial resistance [97]. 
A recent survey found that over 99% of retinal specialists 
use PI before intraocular injections [48].
Efficacy In a small randomized study, 5% PI instilled 
into the conjunctival sac prior to ophthalmic surgery 
reduced the number of bacterial colonies by 91%, com-
pared with a 33% reduction in control eyes [98].
In a subsequent open-label non-randomized parallel 
trial, Speaker and Menikoff found that the incidence of 
culture-positive endophthalmitis was 0.06% in an oper-
ating suite using 5% PI, compared with 0.24% in another 
suite using silver protein solution (P < 0.03) [99].
Safety and toxicity Adverse reactions to PI are usually 
the result of an irritant effect that is proportional to the 
duration of exposure, and consequently many patients 
report post-injection pain [100, 101]. A study in rabbits 
demonstrated significant epithelial fluorescein staining 
with 5% PI [102]. It should be irrigated thoroughly post-
injection to minimize discomfort [100]. Less commonly, 
contact dermatitis may develop after repeated exposure 
[100, 101].
If PI is applied to the surface of the eye just before the 
needle is inserted through the pars plana, a small amount 
of PI may be introduced into the vitreous cavity [103]. 
Animal studies have shown that intravitreal injection of 
a small volume of low-concentration PI is well tolerated 
[104, 105].
Anaphylaxis to PI is rare, and there have been no 
reports of anaphylaxis following the topical ophthalmic 
use of PI [100, 103]. Furthermore, seafood allergy is not 
a contraindication to the use of topical PI, nor is reported 
allergy to iodinated contrast media [100]. Iodine is not 
the allergenic component of shellfish or contrast media, 
even though both contain iodine [100, 101, 106].
Method of  instillation A 10  mL flush of PI onto the 
conjunctival surface and fornices has been shown to lower 
conjunctival bacterial counts more than simply instilling 
a few drops [93, 107]. Flushing is thought to dislodge bac-
teria from the fornices, where the conjunctiva has many 
deep crypts, allowing PI to kill the organisms [93]. Selec-
tively flushing one quadrant of the conjunctival surface 
while avoiding the cornea has not been compared with 
bathing the entire ocular surface. While PI may be applied 
to the eyelid margins and eyelashes, eyelid scrubbing 
should be avoided [108, 109].
Concentration and  contact/kill‑time Half-strength 
(5%) PI is commonly used on the ocular surface to reduce 
its epithelial toxicity, but the most effective concentration 
is debatable [110].
Berkelman et al. [111] demonstrated that diluting full-
strength (10%) PI paradoxically increased its bactericidal 
activity against S. aureus in vitro. After a 15 s exposure to 
PI, no organisms were recovered using concentrations of 
0.1, 0.2 or 1% PI, but sterility was not achieved with such 
a short exposure using 5% or 10% PI. A 1–2 min exposure 
to 5% PI and a 4 min exposure to 10% PI was required to 
achieve sterility.
Ta et  al. [112] found no difference in the conjunctival 
culture rates using 5% PI for 1 min, compared with 10% 
PI for 5 min. Van Rooij et al. [113] reported no increase in 
their rate of post-cataract surgery endophthalmitis, after 
switching from 5 to 1% PI. Shimada et al. [27] described a 
series of 15,144 injections using 0.25% PI, without a sin-
gle case of endophthalmitis.
In contrast, using a 2-min contact time, Ferguson et al. 
[110] found that 5% PI was more effective than 1% PI at 
reducing the number of colony forming units, particu-
larly in the presence of a heavier initial bacterial load. 
While the concentration of free iodine may be higher at 
lower concentrations of PI, it is thought that a lower con-
centration of PI has a lower reservoir of available iodine, 
which is exhausted when the bacterial load is increased.
Friedman et  al. [114] found a significant reduction in 
conjunctival bacterial growth after a 30 s exposure to 5% 
PI, and a further reduction with a 60+ second exposure, 
while 15 s was inadequate.
Post‑injection antisepsis Post-injection PI may reduce 
the risk of subsequent bacterial entry via a “vitreous 
wick” through the wound track. The role of this potential 
mechanism for endophthalmitis is unclear. Apt et al. [115] 
showed that 5% PI instilled at the conclusion of cataract 
surgery suppressed bacterial growth more than an anti-
biotic solution, for 24 h following surgery. Shimada et al. 
[27] used a 5 mL flush of 0.25% PI before and after injec-
tions with an endophthalmitis rate of 0/15,144.
Resistance Hsu et  al. recently showed that bacterial 
resistance does not develop in patients undergoing serial 
intravitreal injections with povidone-iodine preparation 
alone, without the use of pre- or post-injection topical 
antibiotics, confirming previous in vitro work [116–118].
Aqueous chlorhexidine
Chlorhexidine is a cationic biguanide that damages the 
outer bacterial surface layers and subsequently attacks 
the cytoplasmic membrane of the organism [95]. Chlo-
rhexidine, like PI, is a broad-spectrum antimicrobial 
agent. Compared with PI, chlorhexidine may act less 
rapidly, but exhibits sustained antimicrobial activity, 
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and is not readily neutralized by organic matter [95, 
119].
Efficacy The mean reduction in conjunctival bacte-
rial counts prior to corneal suture removal using a 3 min 
exposure to 4% PI was 91%, compared with 88% using 
0.05% chlorhexidine, a non-statistically significant differ-
ence [120]. In another study, there was no difference in the 
culture rate from conjunctival swabs in patients receiving 
either 0.05% chlorhexidine or 0.6% PI [121].
In a multi-center retrospective study where aque-
ous chlorhexidine gluconate 0.1% was used as the sole 
antiseptic measure prior to intravitreal injection, the 
endophthalmitis rate was 3/40,535 (0.0074%; 1 in 13,512) 
[Personal communication, Dr Peter Davies, Newcastle, 
NSW Australia].
Safety and toxicity The safety of aqueous chlorhexidine 
has been detailed in numerous animal studies [122–124], 
however alcohol-based or detergent-based chlorhexidine 
causes severe corneal epithelial toxicity [125]. Topical 
chlorhexidine 0.02% to 0.2% is used as a treatment for 
acanthamoeba keratitis [126]. While endothelial toxicity 
is well described, a significant concentration of chlorhex-
idine is unlikely to reach the endothelium after intravitreal 
anti-VEGF injection [127–129].
Resistance The acquisition of resistance to chlorhex-
idine has been demonstrated in  vitro but whether it 
occurs on the ocular surface after repeated intravitreal 
injections is yet to be studied [117]. The reduced suscep-
tibility of methicillin-resistant S. aureus (MRSA) to chlo-
rhexidine compared with methicillin-sensitive S. aureus, 
and the presence of efflux-mediated resistance genes in 
staphylococci is of concern [130].
Povidone‑Iodine + chlorhexidine
Synergy when using both PI and chlorhexidine has been 
described in vitro and in clinical studies on the skin, but 
has not been studied on the eye [95, 131, 132].
Saline irrigation alone
Irrigation with saline alone has been shown to be ineffec-
tive in reducing the conjunctival bacterial load and may 
even increase bacterial counts, perhaps because bacte-
ria are dislodged from the fornices but not subsequently 
killed. [114, 133, 134]
In summary, the optimal concentration and contact-
time for antiseptic agents likely depends on the bacte-
rial load, the spectrum of bacteria present and their 
virulence, and the robustness of the host defense mecha-
nisms. While a longer contact time may lead to a greater 
reduction in the bacterial load, it may be complicated by 
more epithelial toxicity. With either agent, our practice is 
to copiously irrigate the ocular surface with normal saline 
after the procedure, to minimize epithelial toxicity. For 
patients who have experienced severe pain after an injec-
tion we have recommended they use preservative-free 
lubricants for a day prior to their subsequent injections 
with good effect.
Anesthesia
Anesthesia prior to intravitreal injection can be achieved 
using topical drops (alone or on a sterile cotton-tipped 
applicator or pledget), viscous gel, subconjunctival injec-
tion or a combination of these [135, 136]. Drops are typi-
cally used prior to gel or subconjunctival injection.
Viscous gel anesthesia
Lidocaine gel has been shown to act as a barrier prevent-
ing PI from coming into contact with bacteria on an agar 
plate [137], and was shown to be a risk factor for post-
operative endophthalmitis if applied prior to PI [138]. No 
cases of endophthalmitis were found in a series of 4,690 
injections where PI was instilled both before and after 
application of lidocaine 2% gel [139]. In vitro, application 
of PI for a mere 5 s prior to lidocaine gel application has 
been shown to be effective in inhibiting bacterial growth 
[140].
In contrast, Dahl et  al. [141] found reduced col-
ony forming units in eyes when lidocaine 2% gel was 
applied before PI, compared with when PI was used 
alone (P = 0.08). Lidocaine gel plated with S. aureus and 
Escherichia coli showed a ring of inhibition to both bac-
teria, suggesting that lidocaine gel might independently 
exert an antimicrobial effect. Lad et  al. found no differ-
ence in the post-injection endophthalmitis rate when 
lidocaine gel was applied prior to PI (4/4,682; 0.085%), 
compared to when PI was used alone (4/4,120;0.097%) 
(P = 1.00) [142]. Although gel may act as a complete bar-
rier to antiseptic agents on an agar plate, the ocular sur-
face is warm, has continuous tear production and there is 
movement between the globe and the eyelid, all of which 
aid the dispersal of gel.
Subconjunctival anesthesia
In a retrospective series, Tustin et al. reported a rate of 
endophthalmitis of 8/8,189 (0.1%) when subconjuncti-
val lidocaine was not used, compared with 0/6,853 when 
it was used (P =  0.03), suggesting that the use of sub-
conjunctival anesthetic may reduce the risk of endoph-
thalmitis [143]. However, 14 culture-negative cases of 
“possible” endophthalmitis were excluded, nine of which 
were after injection of triamcinolone and five after beva-
cizumab. The same authors found that 2% lidocaine/0.1% 
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methylparaben demonstrated rapid bactericidal effects 
against S. aureus, S. epidermidis and S. viridans in vitro 
[143].
If antiseptics are not used prior to administration of 
subconjunctival anesthetic, surface bacteria may be 
introduced into the subconjunctival space by the needle, 
and these could in turn be introduced into the vitreous 
cavity [144]. Nonetheless, Tustin et al. [143] only applied 
PI after the subconjunctival injection of anesthetic, and 
not before, with no cases of definite endophthalmitis.
While lidocaine may have inherent bactericidal prop-
erties, the reduction in endophthalmitis risk with sub-
conjunctival lidocaine that Tustin et  al. reported may 
be the result of other factors. The bleb of anesthetic 
may help to disconnect the vitreous body from the con-
junctival surface, or dilute the pathogens that are pre-
sent. As subconjunctival anesthesia works best if left 
for at least a few minutes, it allows the povidone-iodine 
to remain in contact with the ocular surface for longer 
than usual. Finally, adequate anesthesia is crucial so 
that the patient does not move or squeeze their eyes as 
the needle enters the eye, as these sudden involuntary 
responses can compromise the sterility of the needle. 
With the deeper anesthesia afforded by subconjuncti-
val injection, this may be another explanation for their 
results.
The application of antiseptic agents before and after 
gel or subconjunctival anesthetic is important, and any 
intrinsic antimicrobial activity of lidocaine should not 
be relied upon. When gel anesthesia is used, the authors 
remove any residual gel by rolling a sterile cotton-tipped 
applicator over the conjunctival surface prior to flushing 
with more PI.
Antibiotics
In the ASRS PAT Surveys the percentage of respondents 
using pre-injection antibiotics was 40% in 2008, 39% in 
2009 and 27% in 2011 [34]. The percentage using them 
post-injection was 86% in 2008, 82% in 2009 and 62% in 
2011. In 2013, 78% of US respondents indicated no use of 
pre- or post-injection antibiotics.
Pre‑injection antibiotics
There have been no prospective studies showing that pre-
injection antibiotics reduce the risk of endophthalmitis. 
Isenberg et al. reported synergy between antibiotics and 
PI, with sterile conjunctival cultures found in 31% of eyes 
treated with a 3  day course of pre-operative antibiotics 
alone and in 40% treated with PI alone, compared with 
sterile cultures in 83% of eyes that received both antibiot-
ics and PI [145]. However, given the longer kill-time of 
antibiotics compared with PI, using antibiotics just 1–2 h 
pre-operatively conferred no additional benefit over PI 
alone in two studies [146, 147].
In a study of patients undergoing regular intravitreal 
injections, the rate of positive bacterial cultures was 8% 
in the group that received a 3 day course of pre-injection 
gatifloxacin in addition to PI, compared with just 4% 
in the group that received PI alone (P = 0.32) [69]. The 
lack of synergy may be a reflection of increased antibi-
otic resistance in patients having regular injections with 
repeated antibiotic exposure, as compared with patients 
about to undergo cataract surgery who are relatively anti-
biotic naive.
Post‑injection antibiotics
Antibiotics have been used post-injection, but not 
pre-injection, in several series without the prevention 
of endophthalmitis (see Table  1) [17, 19, 22, 25, 26, 31, 
32]. In fact, a non-statistically significant higher rate of 
endophthalmitis has been found in patients receiving 
post-injection antibiotics in a number of studies [16, 28, 
148–150].
Antibiotic resistance
Coagulase-negative Staphylococcus endophthalmitis 
isolates resistant to fluoroquinolones at Bascom Palmer 
Eye Institute increased from 0 to 10% in 1990–1994, to 
17–21.8% in 1995–1999, to 26.9–38.4% in 2000–2004, to 
57.8–60.5% in 2005–2011 [151–153]. It is suspected that 
the widespread use of fluoroquinolones is responsible for 
the increasing resistance.
In 2010, the Antibiotic Resistance of Conjunctiva 
and Nasopharynx Evaluation (ARCaNE) investigators 
reported a significant baseline level of bacterial resist-
ance in the conjunctiva of patients with newly diagnosed 
choroidal neovascularisation [67]. They subsequently 
showed that repeated intermittent exposure of ocular 
flora to topical antibiotics selected for resistant strains, 
which emerged immediately after exposure to antibiotic, 
and were maintained by periodic re-exposure [154, 155]. 
Co-resistance to other antibiotics also developed [156].
In another study, eyes receiving a 4-day course of fluo-
roquinolones after each injection were found to have a 
resistance rate of 87.5% compared with 25% in control 
eyes [157]. In a larger prospective study, a 3-day course 
of topical moxifloxacin after each injection increased the 
percentage of resistant isolates from 0% at baseline to 
50% at month three [68].
In an animal study of experimentally-induced S. epider-
midis endophthalmitis, antibiotic-resistant strains caused 
more inflammation and destruction of the infected ret-
ina compared with antibiotic-susceptible strains [158]. 
The same authors also noted that only antibiotic resist-
ant strains of S. epidermidis have been isolated from 
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their patients with post-operative endophthalmitis. It is 
postulated that antibiotic resistance leads to coloniza-
tion by more virulent bacterial strains that can overcome 
the host defense mechanisms more easily, resulting in a 
higher likelihood of endophthalmitis [28, 159]. Antibi-
otic-resistant strains may also be more difficult to treat.
Antibiotic penetration
It has been shown that the topical administration of 
second-generation (ciprofloxacin, ofloxacin) and fourth-
generation (moxifloxacin, gatifloxacin) fluoroquinolones 
leads to effective levels in the aqueous but not in the vit-
reous, in the non-inflamed eye [160, 161].
In summary, topical antibiotics not only have minimal 
vitreous penetration and seem to be unhelpful in pre-
venting endophthalmitis, but with increasing resistance 
and selection of more virulent strains, routine antibiotic 
use could be harmful and we do not recommend their 
use either pre- or post-injection. Pre-injection topical 
antiseptics must be used, and to alleviate post-injection 
discomfort, patients can use preservative-free lubricants.
Speculum
It is critically important to avoid contaminating the needle 
with the eyelashes or lid margins before or during entry 
into the globe, as direct inoculation is considered to be the 
major mechanism by which endophthalmitis occurs [108, 
162]. A speculum is a reliable way to isolate the injection 
site, but many patients find them uncomfortable.
In a survey of retinal specialists in the USA, 92% of 
respondents stated that they routinely use an eyelid 
speculum to keep the eyelashes away during intravit-
real injections [48]. A closed-blade speculum is superior 
to an open-blade speculum as it covers the eyelashes 
more effectively [163], but the most temporal lashes may 
remain exposed with any speculum. In some patients, 
excessively long eyebrow hairs also need to be avoided. 
In eight of the 12 patients with endophthalmitis in the 
VISION study, the infection was associated with protocol 
violations, the most common being failure to use an eye-
lid speculum [162].
Insertion of a speculum could theoretically squeeze 
secretions and bacteria out of the Meibomian glands, 
particularly in patients who forcefully squeeze their eye-
lids against the speculum. For this reason, it has been 
recommended that further PI should be instilled after 
speculum insertion [35, 108]. In a randomized controlled 
study, Friedman et  al. [114] recently showed that the 
placement of a lid speculum did not in fact increase the 
number of conjunctival bacterial colony forming units.
Tailor et al. [164] found that the insertion of a lid speculum 
was the third most uncomfortable step during an intravitreal 
injection. Fineman et al. [32] found that a two-person biman-
ual eyelid retraction technique has the advantage of less 
patient discomfort. In their series of 10,164 injections with-
out the use of a speculum there were three cases of 
endophthalmitis (0.03%). One-person bimanual retraction 
techniques using the fingers [165], a cotton-tip applicator 
[166], or a Desmarres lid retractor [167] have recently been 
described. In the PIE study, the endophthalmitis rate was 
13/12,500 (0.10%) with the use of a bladed lid speculum, 
compared with 10/15,236 (0.066%) without (P = 0.27) [168].
While the experience in the VISION study made a 
compelling argument for the use of eyelid speculums, 
more recent evidence suggests that alternative methods 
of isolating the eyelids and eyelashes may be acceptable. 
With or without a speculum, we believe that if a needle 
has inadvertently touched anything but the bulbar con-
junctiva at the injection site before or during entry into 
the eye it should be immediately withdrawn and dis-
carded to avoid inoculating the vitreous. While PI may be 
applied to the eyelid margins and eyelashes, the adnexae 
should still be considered non-sterile.
Sterile drapes
In a survey of retinal specialists in the USA, 668 of 759 
respondents (88%) reported not using a sterile drape [48]. 
It has been suggested that a sterile adhesive drape isolates 
the patient’s nose and oropharynx from their eye, and 
theoretically could reduce bacterial aerosolization origi-
nating from the patient [19, 70].
In a study evaluating patients’ experiences at different 
stages of the injection procedure, the application, cutting 
and removal of an adhesive drape were found to be the 
most uncomfortable aspects of the procedure, bar the 
injection itself [164].
Sterile drapes allow the physician to position the 
patient’s head without contaminating their sterile gloves. 
It is unclear how important they are in reducing the risk 
of endophthalmitis given that their use is often associated 
with other aseptic measures including the use of sterile 
gloves and face masks.
Techniques to minimize vitreous reflux
When an intravitreal injection needle is withdrawn from 
the eye, a subconjunctival bleb forms in approximately 
one-third of cases [169]. It is thought to comprise liq-
uefied vitreous as well as some of the injected drug 
[170–172], but the presence of reflux does not lead to a 
subtherapeutic effect [173]. There is a theoretical risk of 
endophthalmitis occurring when organisms gain entry 
into the vitreous cavity through a “vitreous wick” [174]. 
Turgut et  al. [175] found less vitreous reflux with injec-
tions performed through the inferotemporal quadrant 
compared with the superotemporal quadrant.
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Displacement of the conjunctiva with a sterile cotton 
tip applicator before injection is thought to provide a dis-
connect between the vitreous cavity and the external eye, 
keeping the vitreous wick subconjunctival [35]. In the PIE 
study this technique was not associated with a reduced 
risk of endophthalmitis [168]. Inoculation of the vitreous 
with a cotton fiber has been reported as a complication 
[176, 177]. Applying pressure to the injection site imme-
diately after needle withdrawal has also been advocated 
to help reduce the amount of vitreous reflux [174].
Tunneled injections through the sclera are associated 
with less vitreous reflux compared with straight injec-
tions that enter the sclera perpendicularly [178–180]. The 
most commonly used needle size for anti-VEGF injec-
tions is 30G [48]. 31G and 32G needles have been shown 
to produce less vitreous reflux in patients [181, 182] and 
in live rabbits [170], however in one cadaveric study [183] 
more reflux was found with 32G compared with 30G 
needles.
The reduced vitreous reflux with 32G needles or tun-
neled injections is associated with a higher immediate, 
though transient, intraocular pressure (IOP) elevation 
[179, 180, 184, 185]. Hoang et al. [184] have reported that 
repeated intravitreal injections in an eye may be compli-
cated by sustained elevations in IOP. They have discussed 
possible mechanisms by which long-term ocular hyper-
tension could result, and have hypothesized that repeated 
injections with minimal reflux may cause mechanical 
expansile stress on the trabecular meshwork.
In summary, techniques to minimize vitreous reflux 
have not been proven to reduce the risk of endophthalmi-
tis and may be associated with more ocular hypertension.
Disinfection of drug vials
The pharmaceutical companies and the Centre for Dis-
ease Control recommend that the rubber diaphragm of 
a drug vial should be disinfected with alcohol prior to 
drawing medication [186].
Buckley et  al. [187] found that the diaphragm of one 
single use vial was contaminated with Staphylococcus 
epidermidis, while the other 99 they examined were ster-
ile. Hilliard et al. [188] reported contamination of the dia-
phragm in two out 12 vials, despite an intact dust plastic 
cover.
In short, disinfection of the rubber diaphragm of vials 
with an alcohol swab is recommended, but the use of pre-
filled syringes eliminates this step.
Same day bilateral Intravitreal Injections
For patients with bilateral disease requiring relatively fre-
quent dosing, bilateral same day injections can reduce 
the burden of treatment. In the 2013 ASRS PAT survey 
50% of respondents reported doing same day bilateral 
injections compared with only 27% in 2008 [34].
Tabatabaii et al. [189] have reported two cases of bilat-
eral endophthalmitis following bevacizumab, resulting in 
20/400 vision bilaterally in one patient and light percep-
tion bilaterally in another.
Pooling the results of eight series, out of 3708 epi-
sodes of bilateral anti-VEGF injections (7,416 injections), 
there have been three cases of unilateral culture-positive 
endophthalmitis, one case of unilateral culture-negative 
endophthalmitis, and one case of unilateral intraocular 
inflammation [190–197].
Numerous outbreaks of endophthalmitis after injec-
tion with compounded bevacizumab have been reported, 
and are thought to be due to contamination during 
syringe preparation at the compounding pharmacy. 
Goldberg et al. [198] have suggested using bevacizumab 
syringes from two different batches for bilateral same-day 
injections.
Given the low risk, bilateral injections appear appro-
priate in select patients. While bilateral injections should 
be considered as two separate procedures, with separate 
instruments and ideally drug from different lots, they 
cannot be truly independent given that the patient is 
likely to have similar risk factors in both eyes, for exam-
ple similar conjunctiva flora [198–200]. The surgeon is 
likely to employ similar aseptic measures and technique 
in both eyes and in many centers only one procedure 
room is available.
Conclusion
Each step of the intravitreal injection procedure has been 
examined, and the relative importance of each aspect in 
lowering the risk of endophthalmitis can be debated at 
length.
From the available evidence, we believe that antibiotics 
pre- or post-injection should be omitted, placing further 
importance upon the need for adequate pre-injection 
antisepsis, which should be applied both before and after 
gel or subconjunctival anesthetic. We advocate the wear-
ing of face masks or maintaining silence given the risk of 
aerosolization of bacteria. Exposure of the injection site 
can be achieved with or without a speculum and the nee-
dle must not make contact with anything before entering 
the eye. Adhering to strict aseptic technique in an office 
or operating room may help achieve the goal of lower-
ing the risk of endophthalmitis following intravitreal 
injection.
The major weakness of this review is that it relies heav-
ily upon retrospective data with the inherent selection 
biases of such studies. Prospective studies will allow 
firmer recommendations to be made in the future.
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